Clinical Trial: A prospective, observational study on the efficacy and safety of ruxolitinib phosphate cream combined with autologous blood therapy in the treatment of non-segmental vitiligo (China)

Posted On: 2026-10-26

China, Oct. 26 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, observational study on the efficacy and safety of ruxolitinib phosphate cream combined with autologous blood therapy in the treatment of non-segmental vitiligo'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135077

Registration Time: 2026/10/23

Type: Observational study

Primary Sponsor: Guangzhou Institute of Dermatology

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=349072

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: A prospective, observational study on the efficacy and safety of ruxolitinib phosphate cream combined with autologous blood therapy in the treatment of non-segmental vitiligo (China)